Venture capital firm Essex Woodlands Health Ventures led the $45m round for Revance Therapeutics, which also included CNF Investments and others.
Revance Therapeutics, a US-based beauty company, has raised $45m from a consortium including CNF Investments, the $225m corporate venturing unit of Clark Enterprises, as a new investor.
Venture capital firm Essex Woodlands Health Ventures led the round, which also included peers NovaQuest Capital after its independence from drugs group Quintiles in November, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors and Pac-Link Ventures.
Jonathan Tunnicliffe, a partner at NovaQuest, will join Revance’s board and said: "The market for botulinum toxin neuromodulators [to smooth facial wrinkles] is already very large and growing and we believe that the Revance technologies for the first topically applied dose form and next generation injectable product are highly differentiated from current offerings and will expand the market further."
In January last year, Revance initially said it closed its series D round at an undisclosed size having previously raised $8m in November 2008.
